Author:
Algazi A.,Bhatia S.,Agarwala S.,Molina M.,Lewis K.,Faries M.,Fong L.,Levine L.P.,Franco M.,Oglesby A.,Ballesteros-Merino C.,Bifulco C.B.,Fox B.A.,Bannavong D.,Talia R.,Browning E.,Le M.H.,Pierce R.H.,Gargosky S.,Tsai K.K.,Twitty C.,Daud A.I.
Reference19 articles.
1. IL-12 family cytokines: immunological playmakers;Vignali;Nat Immunol,2012
2. Inflammatory cytokines as a third signal for T cell activation;Curtsinger;Curr Opin Immunol,2010
3. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response;Gollob;Clin Cancer Res,2000
4. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993;Atkins;J Clin Oncol,1999
5. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma;Motzer;Clin Cancer Res,1998
Cited by
95 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献